IP Library Granted Patent US 7,338,930
Granted Patent B2
US 7,338,930 · App. 11/312,797 · Granted Mar 4, 2008

Methods of treating osteoarthritis using IL-17 receptor proteins in combination with TNF-receptor proteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,338,930
App. No.
11/312,797
Granted
Mar 4, 2008
Kind
B2
Abstract

Methods for regulating levels of nitric oxide are disclosed. The methods utilize IL-17 receptors, which may be used in conjunction with inhibitor of IL-1 and/or TNF.

Claims (10)

1. A method of treating a mammal afflicted with osteoarthritis, the method comprising administering to said mammal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein is selected from the group consisting of:

(a) a protein comprising amino acids 28 through 320 of SEQ ID NO:4;

(b) a protein comprising an amino acid sequence that is at least 80% identical to the amino acid sequence of (a) that binds IL-17; and

(c) a fragment of (a) that binds IL-17; and

administering a soluble Tumor Necrosis Factor (TNF) receptor protein formulated in a pharmaceutically acceptable diluent or carrier to said mammal.

2. The method of claim 1 , wherein the soluble IL-17R protein comprises amino acids 28 through 320 of SEQ ID NO:4.

3. The method of claim 1 , wherein the soluble IL-17R protein comprises a protein having an amino acid sequence that is at least 80% identical to amino acids 28 through 320 of SEQ ID NO:4 and binds IL-17.

4. The method of claim 1 , wherein the soluble IL-17R protein comprises a fragment of amino acids 28 through 320 of SEQ ID NO:4 that binds IL-17.

5. The method according to claim 1 , wherein the soluble IL-17R protein further comprises an Fc domain.

6. The method according to claim 1 , wherein the soluble IL-17R protein further comprises an oligomerizing domain.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2013
From: AMGEN INC.
To: KIRIN-AMGEN, INC.
Reel/Frame 030045/0876 →